Faster global financial news!
BioNTech
-
BioNTech's lung cancer drug gotistobart shows significant overall survival benefit in Phase 3 trial
BioNTech (NASDAQ:BNTX) reported that its investigational lung-cancer drug gotistobart produced a clinically meaningful overall-survival benefit in the Phase 3 PRESERVE-003 trial for patients with meta
-
BioNTech shares fell 1.2% in premarket trading after BMO downgraded the stock and cut its price target from $128 to $105, citing declining vaccine demand and the termination of a cancer vaccine trial.
BioNTech shares fell 1.2% in premarket trading after BMO downgraded the stock and cut its price target from $128 to $105, citing declining vaccine demand and the termination of a cancer vaccine trial.
-
BioNTech shares tumble 8% after terminating Phase 2 colorectal cancer vaccine trial due to futility
BioNTech's stock fell to $102.38 after the company announced it had scrapped its Phase 2 BNT122-01 colorectal cancer vaccine trial, developed with Genentech, as an independent Data Safety Monitoring B
-
Moderna shares drop 7% despite a recent Wolfe Research upgrade, while BioNTech slips 2%
Moderna (NASDAQ:MRNA) stock fell 7% to $148.02 midday Wednesday, giving back a large portion of Tuesday's 14% rally that followed Wolfe Research's upgrade to Peer Perform from Underperform. BioNTech S
-
Moderna shares fall 7% to $135.22 as traders engage in profit-taking after a 392% year-to-date surge; BioNTech falls 4%, Merck falls 1%.
Moderna (MRNA) shares fell 7% to $135.22 in early trading Monday, after rising 392% year-to-date, as traders opted for profit-taking in the absence of new negative catalysts. Over the same period, Bio
-
BioNTech's lung cancer drug gotistobart shows significant overall survival benefit in Phase 3 trial
BioNTech (NASDAQ:BNTX) reported that its investigational lung-cancer drug gotistobart produced a clinically meaningful overall-survival benefit in the Phase 3 PRESERVE-003 trial for patients with meta
-
BioNTech shares fell 1.2% in premarket trading after BMO downgraded the stock and cut its price target from $128 to $105, citing declining vaccine demand and the termination of a cancer vaccine trial.
BioNTech shares fell 1.2% in premarket trading after BMO downgraded the stock and cut its price target from $128 to $105, citing declining vaccine demand and the termination of a cancer vaccine trial.
-
BioNTech shares tumble 8% after terminating Phase 2 colorectal cancer vaccine trial due to futility
BioNTech's stock fell to $102.38 after the company announced it had scrapped its Phase 2 BNT122-01 colorectal cancer vaccine trial, developed with Genentech, as an independent Data Safety Monitoring B
-
Moderna shares drop 7% despite a recent Wolfe Research upgrade, while BioNTech slips 2%
Moderna (NASDAQ:MRNA) stock fell 7% to $148.02 midday Wednesday, giving back a large portion of Tuesday's 14% rally that followed Wolfe Research's upgrade to Peer Perform from Underperform. BioNTech S
-
Moderna shares fall 7% to $135.22 as traders engage in profit-taking after a 392% year-to-date surge; BioNTech falls 4%, Merck falls 1%.
Moderna (MRNA) shares fell 7% to $135.22 in early trading Monday, after rising 392% year-to-date, as traders opted for profit-taking in the absence of new negative catalysts. Over the same period, Bio
- No data
BioNTech
24H Trending
-
1
BitMart Exchange Has Ceased Operations: A Review of Perpetual Contract Services and Platform Status
-
2
Polkadot (DOT) Ecosystem Expansion: New Projects, Core Upgrades, and Tokenomics Transformation
-
3
Former PlayStation executive criticizes Sony's plan to discontinue physical discs by 2028, stating the move harms the company's reputation.
-
4
Overview of Cryptocurrency Exchanges Supporting USDT Stablecoin
-
5
TXBIT Coin Status Analysis: Token Market and Risks After the Closure of the Original Txbit Exchange
-
6
PROP Coin Value Analysis: Propbase (PROPS) Project and Investment Outlook
-
7
Casper (CSPR) Token Analysis: The State of Enterprise Blockchains and Market Considerations
-
8
China's Cryptocurrency Regulatory Policies and a Global Overview of Trading Platforms
-
9
Securitize is bringing tokenized shares of giants like Apple, NVIDIA, and Tesla to Solana, with plans for listing on the New York Stock Exchange.
-
10
In-depth Analysis of CAKE Token Market Capitalization Trends: PancakeSwap Ecosystem and Deflationary Mechanism
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
